These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26051637)

  • 1. Potential Pathways Involved in the Rapid Antidepressant Effects of Nitrous Oxide.
    Zarate CA; Machado-Vieira R
    Biol Psychiatry; 2015 Jul; 78(1):2-4. PubMed ID: 26051637
    [No Abstract]   [Full Text] [Related]  

  • 2. Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial.
    Nagele P; Duma A; Kopec M; Gebara MA; Parsoei A; Walker M; Janski A; Panagopoulos VN; Cristancho P; Miller JP; Zorumski CF; Conway CR
    Biol Psychiatry; 2015 Jul; 78(1):10-18. PubMed ID: 25577164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitrous Oxide: an emerging novel treatment for treatment-resistant depression.
    Quach DF; de Leon VC; Conway CR
    J Neurol Sci; 2022 Mar; 434():120092. PubMed ID: 34953347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of nitrous oxide in the treatment of major depressive disorder and treatment-resistant major depressive disorder: A systematic review and meta-analysis nitrous oxide in depressive disorders.
    Rech P; Custodio RM; Rodrigues Uggioni ML; Silveira Prestes G; Marçal F; Silveira VP; Dagostin VS; Colonetti T; Rosa MI
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Feb; 129():110869. PubMed ID: 37813146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploiting N-methyl-d-aspartate channel blockade for a rapid antidepressant response in major depressive disorder.
    Blier P
    Biol Psychiatry; 2013 Aug; 74(4):238-9. PubMed ID: 23885752
    [No Abstract]   [Full Text] [Related]  

  • 6. Brain function changes reveal rapid antidepressant effects of nitrous oxide for treatment-resistant depression:Evidence from task-state EEG.
    Shao X; Yan D; Kong W; Sun S; Liao M; Ou W; Zhang Y; Zheng F; Li X; Li L; Hu B
    Psychiatry Res; 2023 Apr; 322():115072. PubMed ID: 36791487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidepressant augmentation: good news, limitations, and stumbling blocks.
    Kocsis JH
    J Clin Psychiatry; 2015 Apr; 76(4):e526-7. PubMed ID: 25919849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful Treatment of Major Depressive Disorder With Add-On Buprenorphine in a Patient With Previous Nonresponse to Standard Antidepressants.
    Elsayed M; Gahr M; Connemann BJ; Schönfeldt-Lecuona C
    Prim Care Companion CNS Disord; 2017 Sep; 19(5):. PubMed ID: 28972704
    [No Abstract]   [Full Text] [Related]  

  • 9. A word to the wise about ketamine.
    Schatzberg AF
    Am J Psychiatry; 2014 Mar; 171(3):262-4. PubMed ID: 24585328
    [No Abstract]   [Full Text] [Related]  

  • 10. Ketamine for treatment-resistant depression: ready or not for clinical use?
    Rush AJ
    Am J Psychiatry; 2013 Oct; 170(10):1079-81. PubMed ID: 23982324
    [No Abstract]   [Full Text] [Related]  

  • 11. Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression.
    Yang JJ; Wang N; Yang C; Shi JY; Yu HY; Hashimoto K
    Biol Psychiatry; 2015 Feb; 77(3):e19-e20. PubMed ID: 25104172
    [No Abstract]   [Full Text] [Related]  

  • 12. Electroconvulsive therapy is a standard treatment; ketamine is not (yet).
    Kellner CH; Greenberg RM; Ahle GM; Liebman LS
    Am J Psychiatry; 2014 Jul; 171(7):796. PubMed ID: 24980176
    [No Abstract]   [Full Text] [Related]  

  • 13. Adjunctive medication strategies for treatment-resistant depression.
    Lam RW
    Can J Psychiatry; 2011 Jun; 56(6):315-6. PubMed ID: 21756444
    [No Abstract]   [Full Text] [Related]  

  • 14. Antidepressant response and subthreshold bipolarity in "unipolar" major depressive disorder: implications for practice and drug research.
    Rihmer Z; Dome P; Gonda X
    J Clin Psychopharmacol; 2013 Aug; 33(4):449-52. PubMed ID: 23775059
    [No Abstract]   [Full Text] [Related]  

  • 15. A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression.
    Nagele P; Palanca BJ; Gott B; Brown F; Barnes L; Nguyen T; Xiong W; Salloum NC; Espejo GD; Lessov-Schlaggar CN; Jain N; Cheng WWL; Komen H; Yee B; Bolzenius JD; Janski A; Gibbons R; Zorumski CF; Conway CR
    Sci Transl Med; 2021 Jun; 13(597):. PubMed ID: 34108247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What are the comparative benefits and harms of augmentation treatments in major depression?
    Shelton RC
    J Clin Psychiatry; 2015 Apr; 76(4):e531-3. PubMed ID: 25919851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Resistant Depression with Loss of Antidepressant Response: Rapid-Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule.
    Lauterbach EC
    Psychopharmacol Bull; 2016 Aug; 46(2):53-58. PubMed ID: 27738380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The TNF-alpha inhibitor etanercept as monotherapy in treatment-resistant depression - report of two cases.
    Schmidt FM; Kirkby KC; Himmerich H
    Psychiatr Danub; 2014 Sep; 26(3):288-90. PubMed ID: 25191779
    [No Abstract]   [Full Text] [Related]  

  • 19. Ketamine as an alternative treatment for treatment-resistant depression.
    Dowben JS; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991
    [No Abstract]   [Full Text] [Related]  

  • 20. Ketamine for Treatment-Resistant Depression: a New Advocate.
    Pérez-Esparza R
    Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.